Click to search for your profile
Click to search for condition or expert
Click to open main menu
Save Condition
Bookmark
Share
Share
Condition
Acute Myelomonocytic Leukemia
Symptoms, Doctors, Treatments, Advances & More
Overview
Find a Doctor
Latest Advances
Clinical Trials
Condition 101
About Acute Myelomonocytic Leukemia
What are the alternative names for Acute Myelomonocytic Leukemia?
AML-M4
Acute myeloblastic leukemia type 4
AML M4
AMMoL
Top Global Doctors
For Acute Myelomonocytic Leukemia
Bookmark
Click to see options
MS
Elite
Mikkael A. Sekeres
Hematology
Oncology
Internal Medicine
Miami, FL
Bookmark
Click to see options
MP
Elite
Mrinal M. Patnaik
Hematology
Oncology
Internal Medicine
Rochester, MN
Bookmark
Click to see options
CD
Elite
Courtney D. Dinardo
Hematology
Oncology
Internal Medicine
Houston, TX
Bookmark
Click to see options
EW
Elite
Eunice S. Wang
Hematology
Oncology
Internal Medicine
Buffalo, NY
Bookmark
Click to see options
RK
Elite
Rami S. Komrokji
Hematology
Oncology
Cardiology
Tampa, FL
Bookmark
Click to see options
EJ
Elite
Elias J. Jabbour
Hematology
Oncology
Internal Medicine
Houston, TX
Latest Advances
On Acute Myelomonocytic Leukemia
Condition:
Chronic Myelomonocytic Leukemia
Journal:
The Lancet. Haematology
Treatment Used:
Hypomethylating Agents
Number of Patients:
949
Published —
January 29, 2021
This study tested the safety and efficacy of using a non-curative therapy to treat patients with chronic myelomonocytic leukemia.
Condition:
Acute Myeloid Leukemia
Journal:
The Lancet. Haematology
Treatment Used:
10-day Decitabine with Venetoclax
Number of Patients:
168
Published —
September 08, 2020
The study researched the safety and effectiveness of 10-day decitabine with venetoclax for acute myeloid leukemia.
Clinical Trials
For Acute Myelomonocytic Leukemia
Clinical Trial
Status:
Not yet recruiting
Phase:
Phase 1
Intervention Type:
Drug
Participants:
72
Start Date:
December 21, 2021
A Phase 1 Study of MLN7243 (TAK-243) for Either Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome/Chronic Myelomonocytic Leukemia Refractory to Hypomethylating Agents
Clinical Trial
Status:
Not yet recruiting
Phase:
Phase 1/Phase 2
Intervention Type:
Drug
Participants:
44
Start Date:
June 30, 2021
Phase I/II Study of SP-2577 (Seclidemstat) in Combination With Azacitidine for Patients With Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
